Tan Li
Founder chez SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
Fortune : 471 M $ au 31/03/2024
Profil
Tan Li a fondé Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Mme Li est directrice exécutive et directrice générale adjointe de cette société et partenaire exécutive de Urumqi Jintiantu Equity Investment Partnership LP. Mme Li siège également au conseil d'administration de Kymab Ltd, Shenzhen Techdow Pharmaceutical Co., Ltd, Shenzhen Duopule Industrial Development Co., Ltd et Kymab Group Ltd. Elle est titulaire d'un diplôme de premier cycle de l'université du Sichuan.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 30/06/2023 | 408 041 280 ( 32,72% ) | 471 M $ | 31/03/2024 |
Postes actifs de Tan Li
| Sociétés | Poste | Début |
|---|---|---|
| SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. | Founder | 21/04/1998 |
| Urumqi Jintiantu Equity Investment Partnership LP | Corporate Officer/Principal | 09/08/2013 |
| Shenzhen Techdow Pharmaceutical Co., Ltd. | Director/Board Member | - |
Shenzhen Duopule Industrial Development Co., Ltd.
 Shenzhen Duopule Industrial Development Co., Ltd. Wholesale DistributorsDistribution Services Part of Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Shenzhen Duopule Industrial Development Co., Ltd. distributes biochemical products. The private company is based in Shenzhen, China. Shenzhen Duopule Industrial Development Co. was acquired by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. on May 31, 2017 for $414.58 million. | Director/Board Member | 13/01/2014 |
Kymab Ltd.
 Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Director/Board Member | - |
Kymab Group Ltd.
 Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The private company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million. | Director/Board Member | 20/01/2017 |
Formation de Tan Li
| Sichuan University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. | Health Technology |
| Entreprise privées | 5 |
|---|---|
| Urumqi Jintiantu Equity Investment Partnership LP | |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
| Shenzhen Techdow Pharmaceutical Co., Ltd. | |
Shenzhen Duopule Industrial Development Co., Ltd.
Shenzhen Duopule Industrial Development Co., Ltd. Wholesale DistributorsDistribution Services Part of Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Shenzhen Duopule Industrial Development Co., Ltd. distributes biochemical products. The private company is based in Shenzhen, China. Shenzhen Duopule Industrial Development Co. was acquired by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. on May 31, 2017 for $414.58 million. | Distribution Services |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The private company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million. | Health Technology |
